Drug resistance in mutant FLT3-positive AML

Abstract

Mutant Fms-Like Tyrosine kinase-3 (FLT3), which is expressed in the leukemic cells of a subpopulation of acute myeloid leukemia (AML) patients, represents an attractive target for the therapy of AML. There are several FLT3 inhibitors presently in clinical trials with sufficient efficacy and toxicity features to warrant further testing in combination with… (More)
DOI: 10.1038/onc.2010.273

4 Figures and Tables

Topics

  • Presentations referencing similar topics